Claro Advisors’s CRISPR Therapeutics CRSP Stock Holding History

Claro Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-5	Closed	–	–	313
2018 Q4	$0	Buy	+5	New	+$174	﹤0.01%	1113

Other funds holding CRSP

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Wellington Management Group

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Claro Advisors's CRSP Position: Q1 2019 in Review

Claro Advisors sold out of CRISPR Therapeutics (CRSP) in Q1 2019, closing a stake of 5 shares.

Claro Advisors first reported a position in CRSP in Q4 2018 and held it in 1 quarter. The position peaked at $0 in Q4 2018. 170 funds tracked by Wall St. Rank hold CRSP as of Q1 2019.

Claro Advisors reported no remaining CRISPR Therapeutics position as of Q1 2019 after selling out during the quarter.
Claro Advisors sold 5 CRISPR Therapeutics shares in Q1 2019.
Claro Advisors first reported a position in CRISPR Therapeutics in Q4 2018 and held it in 1 quarter.
Claro Advisors's CRISPR Therapeutics position peaked at $0 in Q4 2018.
170 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2019.

Based on Claro Advisors's 13F filing for Q1 2019, filed 10 May 2019.